NRF2 inhibition or knockdown restored chemosensitivity in breast, colorectal, pancreatic and gallbladder cancer and is being increasingly discussed as a novel chemotherapy combination strategy [47–49]. Here, NFE2L2 is linked to gallbladder cancer.